Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?

Abstract

The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

“…As there is a similarity between SARS and COVID-19, CP therapy might be a hopeful treatment option for COVID-19 patients. After studies conducted in China to measure the effectiveness of CP therapy, and their impact on the condition of those treated and recovered from infection with the 2019-nCoV, hospitals in New York City are preparing to use the plasma blood of those recovering from the 2019-nCoV as a potential antidote to the disease [73,74]. However, there is a small possibility of risk of using CP therapy by transmission of some blood-borne pathogen to include human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) [75].At least 10 proposed drugs/vaccines for SARS-CoV-2 are under development.…”

Lessons Learned from COVID-19 Pandemic in Italy

“…As of May 2020, nearly 70 days after the beginning of the lockdown in our country (March 10, 2020), a large portion of the health-care personnel has not performed the swab [5]. Specific kits for serological testing that identify and quantify immunoglobulins G and M for SARS-CoV-2 infection are now available and should be performed in healthcare workers andif possiblein the entire population [13]. In the case of serological positivity, a nasopharyngeal swab should be performed, allowing for early identification and isolation of potentially positive subjects.…”

“…Positive individuals should be isolated for a period of at least 4 weeks, and swabs should be performed at home at regular intervals to monitor disease progression and healing. It is important to understand thatto datethe timing of positivity for SARS-CoV-2 immunoglobulins is still unknown and this should be taken into account when declaring a patient as "negative" and discharge him from home or hospital isolation [13].…”

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

“…Aside from repurposing existing therapies, there is an increasing demand for immunotherapy, driven by immunoinformatics and comparison homology sequencing with SARS-CoV to narrow down epitopes as potential candidates to design a peptide vaccine against SARS-CoV-2 (1,4,7,19). Another approach that has been proposed is to passively immunize newly infected patients with IgG antibodies collected from patients that have recovered from COVID-19 (24).…”